Skip to main content
. 2013 Dec 11;13:116. doi: 10.1186/1471-2261-13-116

Table 2.

Study characteristics and baseline characteristics of participants

  CLOSURE PC RESPECT
Study Characteristics
Design
Randomized Controlled trial
Randomized Controlled trial
Randomized Controlled trial
Duration of follow up
2.0 years
4.1 years
2.1 years
Location
Multi-center trial (North America)
Multi-center trial (Europe, Canada, Brazil, Australia)
Multi-center trial (North America)
Total
909
414
980
 
Closure
Medical
Closure
Medical
Closure
Medical
447
462
204
210
499
481
Participants
Age
46.3+/−9.6
45.7+/−9.1
44.3+/−10.2
44.6+/−10.1
45.7+/−9.7
46.2+/−10.0
Male sex
52.1%
51.5%
45.1%
54.3%
53.7%
55.7%
Race or ethnic group
Asian
1.6%
1.7%
NA
NA
NA
NA
Black
4.2%
5.6%
NA
NA
NA
NA
White
89.0%
89.6%
NA
NA
NA
NA
Hispanic
6.7%
4.8%
NA
NA
NA
NA
Smoking during previous year
21.5%
22.6%
22.5%
22.4%
15.0%
11.4%
Birth control/HRT
NA
NA
NA
NA
8.2%
10.8%
Deep venous thrombosis
NA
NA
NA
NA
4.0%
3.1%
Medical history (%)
Hypertension
33.8%
28.4%
24.0%
27.6%
31.7%
31.2%
Hypercholesterolemia
47.4%
40.9%
24.5%
29.5%
38.9%
40.1%
Diabetes Mellitus
NA
NA
2.5%
2.9%
6.6%
8.3%
Migraine
NA
NA
23%
18.1%
39.1%
38.5%
Family history of cardiovascular disease or cerebrovascular accidents
55.3%
55.6%
26.0%
19.0%
27.3%
22.5%
Congestive Heart Failure
0.4%
0%
NA
NA
0.6%
0%
Ischemic heart disease
1.3%
0.9%
2.0%
1.9%
3.8%
1.9%
Myocardial infarction
1.6%
1.1%
1.5%
0.5%
1.0%
0.4%
Valvular dysfunction
11.0%
9.7%
3.9%
2.4%
NA
NA
Arrhythmia
5.8%
4.1%
NA
NA
NA
NA
Peripheral vascular disease
1.1%
1.5%
1.5%
1.0%
1.0%
0.2%
Pulmonary embolus
0
0.9%
NA
NA
NA
NA
Peripheral embolism
NA
NA
2.9%
2.4%
NA
NA
Previous TIA
NA
NA
NA
NA
11.6%
12.7%
Previous Stroke
NA
NA
NA
NA
10.6%
10.6%
Index neurologic event for study entry
Stroke
NA
NA
80.9%
77.6%
NA
NA
Cryptogenic stroke
72.6%
71.4%
NA
NA
100.0%
100.0%
TIA 27.4% 28.6% 16.2% 20.0% NA NA